Webinar on

Genomics & Molecular Biology

May 21, 2021

Genomics & Molecular Biology 2021

Theme: Exploring the New Horizons in Plant Science and Genomics

We are delighted to invite all the participants globally to attend “Webinar on Genomics & Molecular Biology by Meetings International during May 21, 2021, which includes incite keynote and oral Presentation. Genomics & Molecular Biology 2021 emphasizes on the theme "Exploring the New Horizons in Plant Science and Genomics" which aims to discover advances in Genomics in connection to wellbeing differences and also a broadness of different points. This year the world meets up at the global online presentation Genomics & Molecular Biology 2021 to accomplish all inclusive welfare inclusion and the sustainable development goals.  The principle focal point of Genomics & Molecular Biology 2021 is the thriving to vary the analysis cycle in genomics, and Molecular Biology.


Genomics is the investigation of genomes, the entire arrangement of hereditary material inside a life form. Genomics includes the sequencing and examination of genomes. Genomics is additionally worried about the structure, capacity, examination, and advancement of genomes. As opposed to hereditary qualities, which alludes to the investigation of individual qualities and their parts in legacy, genomics utilizes high throughput DNA sequencing and bioinformatics to amass, and examine the capacity and structure of whole genomes.

2.Molecular Biology
Molecular biology concerns the molecular basis of biological activity between the various systems of a cell, including the interactions between the different types of DNA, RNA and proteins and their biosynthesis, and studies how these interactions are regulated. It has many applications like in gene finding, molecular mechanisms of diseases and its therapeutic approaches by cloning, expression and regulation of gene. Research area includes gene expression, epigenetics and chromatin structure and function, RNA processing, functions of non-coding RNAs, transcription. Nowadays, most advanced researches are going on these topics: Molecular biology, DNA replication, repair and recombination, Transcription, RNA processing, Post-translational modification, proteomics, Mutation, Site-directed mutagenesis, Epigenetics, chromatin structure and function, Molecular mechanisms of diseases.

3.Cancer Genomics
Cancer Genomics study has revealed abnormalities in genes that drive the development and growth of many types of cancer. This knowledge has improved our understanding of the biology of cancer and led to new methods of diagnosing and treating the disease. Large number of mutations that drive the development and progression of many types of cancer have been identified through large-scale research studies; some tumor types have not been deeply characterized. New technologies and the knowledge gained from previous genomic studies could be used to define the full set of driver mutations in many cancers.

Pharmacogenomics is a piece of a field called customized solution that means to tweak human services, with choices and medications custom-made to every individual patient inside and out conceivable. Pharmacogenomics and pharmacogenomics manage new developments in the field of customized meds and advancements in modified medication revelation utilizing proteome innovation. Pharmacogenomics aims to customize health care, with decisions and treatments tailored to each individual patient in every way possible. Genomic testing is still a relatively new development in drug treatment, this field is expanding. Currently, more than 100 drugs have label information regarding pharmacogenomics biomarkers. This information is used to improve the selection and dosage of drugs to treat a wide range of conditions, including cardiovascular disease, lung disease, HIV infection, cancer, arthritis, high cholesterol and depression.

5.Genome Medicine
Genomic Medicine "as an emerging medical discipline that involves using genomic information about an individual as part of their clinical care (e.g., for diagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use." Already, genomic medicine is making an impact in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious disease.

6.Microbial Genomics
Microbial Genomics applies recombinant DNA, DNA sequencing routines, and bioinformatics to succession, gather, and dissect the capacity and structure of genomes in organisms. Amid the previous 10 years, genomics-based methodologies have profoundly affected the field of microbiology and our comprehension of microbial species. In view of their bigger genome sizes, genome sequencing endeavor on growths and unicellular eukaryotes were slower to begin than ventures concentrated on prokaryotes.. A microbial genome program based on rational priorities is needed to make strategic decisions about the appropriation and distribution of funding and resources. OpGen filed plans with the U.S. Securities and Exchange Commission to sell 3.75 million shares in an initial public offering with the goal of securing up to $35.2 million. The Gaithersburg, Md.-based microbial genetics analysis company said it will use the money as working capital and to support increased sales and marketing efforts for its genetic tests for multidrug resistance organisms.

7.Genomics Market
Genomics is the study of the genetic material or genomes of an organism. Analysts forecast the Global Genomics market will grow at a CAGR of 11.21% over the period 2013-2018. According to the report, the most important driver of the market is an increase in the demand for consumables. The growing adoption of genetic testing for various applications, especially in regions such as the APAC, and an increase in genetic testing volumes in North America and Western Europe is increasing the demand for consumables.

8.Micro RNA
MicroRNAs constitutes a recently discovered class of non-coding RNAs that play key roles in the regulation of gene expression. According to the International Agency for Research on Cancer (IARC), a specialized agency of the WHO, about 12.7 million new cancer cases were reported in 2008 and the number reached 14.1 million in 2012. MicroRNAs are used as a biomarker for cancer diagnosis and treatment. Some of the major companies operating in the global microRNA market are Affymetrix Inc., Alnylam Pharmaceuticals Inc., Santaris Pharma A/S, Exiqon A/S, AstraZeneca Pharmaceuticals LP, Biogen Idec Inc., Eli Lilly and Co., Pfizer Inc., CBC Comprehensive Biomarker Center GmbH, F. Hoffman-La Roche, GlaxoSmithKline, Merck & Co. Inc., Novartis AG and Sigma-Aldrich. GlaxoSmithKline (GSK) has established collaboration with Regulus Therapeutics to develop and commercialize therapeutics targeting microRNA-122 for hepatitis C virus (HCV) infection.


Growth within the personalised medication market is about to supply Associate in Nursing array of opportunities for players operative within the genetic science market. varied pharmaceutical corporations square measure more and more investment in personalised medication analysis. personalised medication permits medical practitioners to spot the precise wants of a patient then visit medicines and coverings consequently. This approach guarantees higher care outcomes. Moreover, it's expected that advancements within the field of cistron medical aid have the potential to interchange ancient medication and surgeries by facultative doctors to treat a disorder by inserting a cistron into a patient’s cell.The use of personalised medication medical aid is on the increase because it offers price savings, patient compliance, drug safety, early detection of diseases, and improvement of therapies. the appearance of deoxyribonucleic acid and cistron microarray technologies has revolutionized the sphere of personalised medication, creating it doable to grasp the expression of all genes within the human order during a single experiment.Research organizations and even massive pharmaceutical corporations square measure increasing their specialize in preciseness medication for the event of recent medication and illness therapies and clinical testing. In 2020, Chigene and MGI signed a cooperation agreement to alter breakthroughs in preciseness designation victimization whole-genome sequencing. below the terms of this agreement, the 2 corporations can leverage their combined benefits in medical testing supported MGI’s cistron sequencing platform, DNBSEQ-T7, and Chigene’s massive information analysis & storage system to steer the whole-genome sequencing project. In 2019, Thermo Fisher Scientific, Inc. (US) introduced the Oncomine preciseness Assay, Associate in Nursing innovative pan-cancer panel, for its Genexus platform to advance preciseness medication in clinical settings. In 2018, GlaxoSmithKline plc (UK) entered into a four-year collaboration with 23andMe (US) to use human biology to guide drug development. It additionally invested with USD three hundred million in 23andMe as an area of the collaboration